# I-MAB (IMAB)

Source: https://www.quantisnow.com/company/IMAB
Generated: 2026-11-08T18:29:18.974Z

- Ticker: IMAB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- Website: i-mabbiopharma.com

## About

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

## Latest IMAB news and filings

- 2025-10-31 10:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6253552)
- 2025-10-29 23:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6250758)
- 2025-10-29 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6249840)
- 2025-10-29 13:00 UTC [Public Offering] [I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform](https://www.quantisnow.com/insight/i-mab-nasdaq-imab-transitions-to-novabridge-biosciences-nasdaq-nbp-with-6249314)
- 2025-10-28 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6247706)
- 2025-10-24 20:23 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6244680)
- 2025-10-24 16:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6244347)
- 2025-10-24 10:16 UTC [SEC Form 6-K] [Amendment: SEC Form 6-K/A filed by I-MAB](https://www.quantisnow.com/insight/amendment-sec-form-6-ka-filed-by-i-mab-6243999)
- 2025-10-23 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6243795)
- 2025-10-22 16:38 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6241363)
- 2025-10-22 16:35 UTC [I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025](https://www.quantisnow.com/insight/i-mab-to-present-positive-updated-givastomig-monotherapy-data-at-2025-6241362)
- 2025-10-16 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6235628)
- 2025-10-16 20:05 UTC [Public Offering] [I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences](https://www.quantisnow.com/insight/i-mab-announces-intention-to-undertake-strategic-transformation-to-global-biotech-6235580)
- 2025-10-15 12:45 UTC [Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge](https://www.quantisnow.com/insight/cellular-immunotherapy-breakthroughs-fuel-370-billion-market-surge-6233497)
- 2025-10-14 11:00 UTC [I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference](https://www.quantisnow.com/insight/i-mab-to-present-short-talk-on-updated-givastomig-monotherapy-data-at-6231266)
- 2025-10-07 12:00 UTC [Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms](https://www.quantisnow.com/insight/novel-cancer-platforms-converge-as-clinical-data-reshapes-treatment-paradigms-6225547)
- 2025-10-06 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6223777)
- 2025-10-03 12:40 UTC [Analyst Coverage Initiated] [Leerink Partners initiated coverage on I-Mab with a new price target](https://www.quantisnow.com/insight/leerink-partners-initiated-coverage-on-i-mab-with-a-new-price-6221783)
- 2025-09-24 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6210726)
- 2025-09-11 20:36 UTC [SEC Form S-8] [SEC Form S-8 filed by I-MAB](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-i-mab-6198193)
- 2025-09-09 11:57 UTC [Analyst Coverage Initiated] [BTIG Research initiated coverage on I-Mab with a new price target](https://www.quantisnow.com/insight/btig-research-initiated-coverage-on-i-mab-with-a-new-price-6194285)
- 2025-09-08 12:30 UTC [Leadership Update] [I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments](https://www.quantisnow.com/insight/i-mab-announces-acceleration-of-givastomig-investment-and-leadership-appointments-6192648)
- 2025-09-08 12:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6192622)
- 2025-08-25 11:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6176970)
- 2025-08-25 11:00 UTC [Leadership Update] [I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee](https://www.quantisnow.com/insight/i-mab-announces-the-appointment-of-seasoned-biotech-executives-to-the-6176941)
- 2025-08-21 11:00 UTC [Conference Announcement] [I-Mab to Participate in September Investor Conferences](https://www.quantisnow.com/insight/i-mab-to-participate-in-september-investor-conferences-6174222)
- 2025-08-20 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6172787)
- 2025-08-20 11:00 UTC [Conference Announcement] [I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/i-mab-reports-second-quarter-2025-financial-results-and-provides-business-6172772)
- 2025-08-11 11:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6157369)
- 2025-08-11 11:00 UTC [Conference Announcement] [I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers](https://www.quantisnow.com/insight/i-mab-completes-enrollment-in-planned-phase-1b-dose-expansion-study-6157290)
- 2025-08-04 11:30 UTC [SEC Form 424B5] [SEC Form 424B5 filed by I-MAB](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-i-mab-6143897)
- 2025-08-04 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6143834)
- 2025-08-01 12:56 UTC [Everest Medicines Expands Strategic Investment in I-MAB](https://www.quantisnow.com/insight/everest-medicines-expands-strategic-investment-in-i-mab-6142425)
- 2025-08-01 12:00 UTC [I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares](https://www.quantisnow.com/insight/i-mab-announces-pricing-of-65-million-underwritten-offering-of-american-6142285)
- 2025-08-01 10:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6142079)
- 2025-08-01 10:01 UTC [SEC Form F-6EF filed by I-MAB](https://www.quantisnow.com/insight/sec-form-f-6ef-filed-by-i-mab-6142055)
- 2025-07-17 11:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6122959)
- 2025-07-17 11:00 UTC [I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health](https://www.quantisnow.com/insight/i-mab-strengthens-givastomig-intellectual-property-portfolio-through-acquisition-of-bridge-6122925)
- 2025-07-14 11:00 UTC [Conference Announcement] [I-Mab to Present at the BTIG Virtual Biotechnology Conference](https://www.quantisnow.com/insight/i-mab-to-present-at-the-btig-virtual-biotechnology-conference-6118528)
- 2025-07-11 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by I-MAB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-i-mab-6118062)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IMAB
- Earnings history: https://www.quantisnow.com/earnings/IMAB
- Dividend history: https://www.quantisnow.com/dividends/IMAB
- Insider transactions: https://www.quantisnow.com/insiders/IMAB
- Options chain: https://www.quantisnow.com/options/IMAB
- SEC 8-K filings only: https://www.quantisnow.com/company/IMAB/8-k
- RSS and alerts for IMAB: https://www.quantisnow.com/docs/rss-feeds.md